Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. Issue 1 (31st January 2019)

• Record Type: Journal Article
• Authors: Zorowitz, Richard D.; Alexander, David N.; Formella, Andrea E.; Ledon, Fred; Davis, Charles; Siffert, Joao
• Is Part Of: PM&R. Volume 11:Issue 1(2019)
• Page Start: 17
• Page End: 24
• Publication Date: 2019-01-31
• Subjects: Medical rehabilitation -- Periodicals; Physical therapy -- Periodicals; Physical Therapy Modalities -- Periodicals; 615.5
• DOI: 10.1016/j.pmrj.2018.06.003
• Languages: English
• ISSNs: 1934-1482

Abstract

Abstract: Background: Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia, or traumatic brain injury. Objective: To report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS). Design: Open‐label trial evaluating twice‐daily DM/Q over 90 days. Study participants: Adults (n = 113) with a clinical diagnosis of PBA secondary to stroke; stable psychiatric medications were allowed. Methods: PRISM II was an open‐label, 12‐week trial enrolling adults with PBA caused by dementia, stroke (reported here), or TBI. All study participants received DM/Q 20/10 mg twice daily. Study visits occurred at baseline and at days 30 and 90. Setting: 150 U.S. centers. Main Outcome Measurements: Primary efficacy measure was changed from baseline to day 90 in Center for Neurologic Study‐Lability Scale (CNS‐LS) scores. Secondary outcomes included PBA episodes (estimated over 7 days), Clinical and Patient/Caregiver Global Impression of Change (CGI‐C and PGI‐C), Quality of Life‐Visual Analog Scale (QOL‐VAS), SIS, Patient Health Questionnaire (PHQ‐9), and Mini‐Mental State Examination (MMSE). Results: Compared with baseline, CNS‐LS scores (SD) improved by −6.2 (6.1, P < 0.001) at day 30 and − 7.6 (6.7, P < 0.001) at day 90. PBA episodes were reduced by 65% and 75% at day 30 and 90, respectively. Seventy‐five percent of clinicians and 67% of patients/caregivers rated PBA as "much" or "very much improved." All SIS items significantly improved from baseline ( P < 0.05, all). Adverse events included diarrhea (4.4%), headache (3.5%), constipation (2.7%), and dizziness (2.7%); 5.3% had adverse events leading to study discontinuation. Conclusions: DM/Q effectively treated PBA and was associated with global and functional improvement; adverse events were consistent with the known safety profile of DM/Q. Level of Evidence: I